Immunonutrition plus chemoradiation for unresectable esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial studies whether adding an “immunonutrition” nutrition plan to standard chemoradiation can improve outcomes for people with locally advanced, unresectable esophageal squamous cell cancer. It may help the treatment work better by supporting the immune system during therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your age is 18 to 85 years old
- You have esophageal squamous cell cancer (not adenocarcinoma or small-cell)
- Your cancer is locally advanced and was judged unresectable at first diagnosis
- You have not started any prior chemo, radiation, or other cancer treatment
- You can take chemoradiotherapy (no medical reasons you can’t safely receive it)
- You can take part in the study consent process and sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan that combines chemotherapy and immunotherapy before surgery, followed by radiation and immunotherapy after surgery for people with esophageal squamous cell cancer. It aims to see if this approach helps prevent the cancer from coming back.
This trial tests whether adding immunotherapy to standard chemoradiation can help people with unresectable locally advanced esophageal cancer. It aims to improve outcomes for those who cannot have surgery.
This trial tests giving a combination of chemotherapy, radiation therapy, and an immunotherapy drug before surgery for a type of esophageal cancer (squamous cell). The goal is to see if this approach helps shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
This study tests whether giving a combination of chemotherapy, radiation, and an immunotherapy drug (cadonilumab) before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a specific type of esophageal cancer that has not spread to other parts of the body.
This study tests a combination of chemotherapy and immunotherapy before and after standard chemoradiation for people with locally advanced esophageal squamous cell carcinoma. It aims to see if this approach can improve outcomes with manageable side effects.
This trial studies giving immunotherapy (anti–PD-1) together with chemotherapy before surgery for certain locally advanced esophageal squamous cell cancer. The goal is to improve how well the tumor responds before and after the operation.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.